Rigas 1. slimnica SIA
- Address
- lock Available on a paid plan
Rigas 1. slimnica SIA - Advanced Dermatology and Immunology Research Center
Rigas 1. slimnica SIA is a distinguished clinical research facility specializing in dermatological and immunological disorders. The center demonstrates particular expertise in investigating novel therapeutic interventions for complex skin and autoimmune conditions, with a strong focus on Phase 2 and Phase 3 clinical trials evaluating cutting-edge biologic and small molecule therapies.
- Moderate to severe plaque psoriasis and psoriatic arthritis treatment development
- Cardiovascular disease prevention, including atherosclerotic cardiovascular disease and atrial fibrillation management
- Respiratory conditions including chronic obstructive pulmonary disease (COPD) and bronchiectasis
- Advanced immunodermatology including bullous pemphigoid and atopic dermatitis
The center has established itself as a leader in evaluating biologic therapies and targeted oral medications for inflammatory skin diseases, conducting multiple pivotal trials with guselkumab, sonelokimab, nemolizumab, and various JAK inhibitors. Beyond dermatology, Rigas 1. slimnica maintains an active research portfolio in cardiovascular risk reduction, particularly with lipid-lowering therapies like inclisiran, and anticoagulation strategies for atrial fibrillation. The facility's comprehensive capabilities extend to chronic heart failure management with iron supplementation studies, demonstrating their versatility across multiple therapeutic areas and their commitment to addressing unmet medical needs in both common and rare conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 29 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Chiesi Farmaceutici S.p.A.1active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG4trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 80 other sites in Latvia
Therapeutic Area Benchmark — Latvia
Select a therapeutic area to compare against other sites in Latvia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Latvia
Market Share
Country: Latvia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Rigas 1. slimnica SIA
lock Showing 1 of 26 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 29 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Inclisiran | 4 | Unknown | 2021-11-26 | 2023-09-04 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.